Literature DB >> 22508321

Tumour-associated trypsin inhibitor TATI is a prognostic marker in colorectal cancer.

Selja Koskensalo1, Jaana Hagström, Johanna Louhimo, Ulf-Håkan Stenman, Caj Haglund.   

Abstract

BACKGROUND: The tumour-associated trypsin inhibitor TATI is expressed together with trypsin in many cancer forms, and an elevated serum level associates with poor prognosis. TATI can reduce tissue destruction by inhibiting trypsin and other proteinases, and in some cancer forms, its high tissue expression is associated with favourable prognosis. We analyzed the prognostic values of TATI, trypsinogen-1 and trypsinogen-2 immunoexpression from tissue array blocks constructed from surgical specimens of 592 colorectal cancer patients.
RESULTS: TATI positivity correlated negatively with differentiation (p < 0.001) and positively with the histological type of adenocarcinoma (p < 0.001). Trypsinogen-1 and trypsinogen-2 positivity correlated with Dukes' stage (p = 0.045, p = 0.050); the percentage of trypsinogen-1- and trypsinogen-2-positive tumours was lower in metastasized (Dukes' stage C-D) than in local (Dukes' stage A-B) disease. In addition, trypsinogen-2 correlated inversely with differentiation (p = 0.012). In univariate analysis, the expression of TATI associated with more favourable cancer-specific survival (p = 0.010). In multivariate analysis, low TATI (p = 0.044), age (p < 0.001), Dukes' stage (p < 0.001), tumour differentiation (p = 0.020) and location in the rectum (p = 0.006) were independent prognostic factors for adverse outcome. Furthermore, TATI expression was an independent prognostic factor in a subgroup of trypsinogen-1- (p = 0.007) and trypsinogen-2-positive (p = 0.006) tumours.
CONCLUSION: TATI tissue expression is an independent prognostic marker in colorectal cancer.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22508321     DOI: 10.1159/000336080

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  6 in total

1.  PRSS1 mutations and the proteinase/antiproteinase imbalance in the pathogenesis of pancreatic cancer.

Authors:  Qiang Yi; Feng Dong; Liqing Lin; Qicai Liu; Shu Chen; Feng Gao; Qingliang He
Journal:  Tumour Biol       Date:  2015-11-06

2.  Serine Protease Inhibitor Kazal Type 1 (SPINK1) Promotes Proliferation of Colorectal Cancer Through the Epidermal Growth Factor as a Prognostic Marker.

Authors:  Yi-Ting Chen; Shu-Chuan Tsao; Shyng-Shiou F Yuan; Hung-Pei Tsai; Chee-Yin Chai
Journal:  Pathol Oncol Res       Date:  2015-06-03       Impact factor: 3.201

3.  Concomitant tumor expression of EGFR and TATI/SPINK1 associates with better prognosis in colorectal cancer.

Authors:  Selja Koskensalo; Johanna Louhimo; Jaana Hagström; Mikael Lundin; Ulf-Håkan Stenman; Caj Haglund
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

4.  Silencing PRSS1 suppresses the growth and proliferation of gastric carcinoma cells via the ERK pathway.

Authors:  Dongmei Ye; Yuxuan Li; Heliang Zhang; Zhiwei Zhou; Yujie Tang; Peng Wu; Qiang Zhao; Zhiwei Zhang
Journal:  Int J Biol Sci       Date:  2021-03-01       Impact factor: 6.580

5.  Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation, migration, invasion and radiation resistance in rectal cancer patients receiving concurrent chemoradiotherapy: a potential target for precision medicine.

Authors:  Yi-Ting Chen; Tzu-Ting Tseng; Hung-Pei Tsai; Shih-Hsun Kuo; Ming-Yii Huang; Jaw-Yuan Wang; Chee-Yin Chai
Journal:  Hum Cell       Date:  2022-09-02       Impact factor: 4.374

6.  MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.

Authors:  Kati Räsänen; Kien X Dang; Harri Mustonen; Tho H Ho; Susanna Lintula; Hannu Koistinen; Ulf-Håkan Stenman; Caj Haglund; Jakob Stenman
Journal:  Mol Oncol       Date:  2017-12-27       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.